Business
AstraZeneca's Profit Rises 23 Percent to $3.1 Billion on Cancer Drugs and the Company Launches a $1.5 Billion Savings Plan
Older medicines are losing sales to generics, but the company keeps its 2026 outlook and its $80 billion revenue target for 2030.

